{ "schemaVersion": 1, "organisationId": "O-7554374d87fc492e88318f5f7a466352", "slug": "financiere-de-tubize", "name": "FINANCIERE DE TUBIZE", "updatedAt": "2026-10-04T15:06:47.526577Z", "sections": [ { "type": "OVERVIEW", "text": "Financière de Tubize is a Belgian mono-holding company whose sole investment is UCB; it has no commercial or industrial operations of its own [P116594653]. At 31 December 2025, it held 36.28% of UCB’s issued shares and reported total assets of €1.934 billion [P8269019]. Tubize’s role is to act as UCB’s long-term reference shareholder, contributing to its strategy and supporting stability for long-term investment [P107163778][P5594306].\n\nUCB, rather than Tubize, is the operating biopharmaceutical company, focused on immunology and neurology, with a presence in nearly 40 countries [P25111795][https://www.ucb.com/sites/default/files/2026-02/IAR_2025.pdf]. Tubize’s stated purpose includes generating long-term shareholder returns, supporting UCB’s development of treatments for serious illnesses, and fostering a sustainable biopharma ecosystem [P79952569][P10005445]. Tubize reported no employees; for operating scale, UCB reported 2025 revenue of €7.741 billion and 10,117 employees [P36293766][https://www.ucb.com/sites/default/files/2026-02/IAR_2025.pdf].\n[P116594653][P8269019][P107163778][P5594306][P25111795][https://www.ucb.com/sites/default/files/2026-02/IAR_2025.pdf][P79952569][P10005445][P36293766][https://www.ucb.com/sites/default/files/2026-02/IAR_2025.pdf]", "updatedAt": "2026-10-04T15:06:47.526577Z" }, { "type": "PRODUCTS", "text": "Financière de Tubize does not itself market products or provide commercial services: it is a mono-holding company with no commercial or industrial activity, and its sole investment is UCB [P116594653]. Its role is as a long-term shareholder; at 31 December 2025 it held 36.28% of UCB’s issued shares [P18866393].\n\nThe medicines associated with Tubize are products of its investee UCB, not of Tubize. Products named in Tubize’s 2025 reporting include BIMZELX, FINTEPLA, RYSTIGGO and ZILBRYSQ [P80337790]. UCB describes BIMZELX (bimekizumab) as an IL‑17A and IL‑17F inhibitor [https://www.ucb.com/solutions/products/bimzelx]; FINTEPLA (fenfluramine) is used for seizures associated with Dravet and Lennox–Gastaut syndromes [https://www.ucb.com/solutions/products/fintepla]; and RYSTIGGO (rozanolixizumab) and ZILBRYSQ (zilucoplan) are treatments for generalized myasthenia gravis [https://www.ucb.com/solutions/products/rystiggo][https://www.ucb.com/solutions/products/zilbrysq]. No product-sales mix or product contribution to performance applies directly to Tubize, which has no product sales of its own.\n[P116594653][P18866393][P80337790][https://www.ucb.com/solutions/products/bimzelx][https://www.ucb.com/solutions/products/fintepla][https://www.ucb.com/solutions/products/rystiggo][https://www.ucb.com/solutions/products/zilbrysq][https://www.ucb.com/solutions/products/bimzelx][https://www.ucb.com/solutions/products/fintepla][https://www.ucb.com/solutions/products/rystiggo][https://www.ucb.com/solutions/products/zilbrysq]", "updatedAt": "2026-10-04T15:06:47.526577Z" }, { "type": "GEOGRAPHY", "text": "Financière de Tubize is a mono-holding company with no commercial or industrial activity; its geographic exposure is through its 36.28% holding in UCB at 31 December 2025, rather than a separately reported operating or sales footprint [P116594653][P18866393].\n[P116594653][P18866393]", "updatedAt": "2026-10-04T15:06:47.526577Z" }, { "type": "SEGMENTS", "text": "Financière de Tubize’s FY2025 reporting describes it as a holding company whose core focus is the long-term holding in UCB, an innovative global biopharmaceutical business. At 31 December 2025, Tubize held 36.28% of UCB’s issued shares. [P107163778][P25111795][P18866393]\n\nTubize does not report business segments or segment contribution percentages: it states that it is not required to prepare consolidated accounts, and its statutory company accounts do not provide an operating-segment breakdown. Accordingly, no segment percentages are disclosed. [P29783943]\n[P107163778][P25111795][P18866393][P29783943][https://www.financiere-tubize.be/wp-content/uploads/2026/03/20260325-RA-2025-UK.pdf]", "updatedAt": "2026-10-04T15:06:47.526577Z" }, { "type": "HISTORY", "text": "Financière de Tubize dates to 1928. Company records describe Tubize as becoming part of the Janssen family that year; UCB was also created in 1928, as a separate milestone, by Emmanuel Janssen. [P55883835][P108848728][P25111795]\n\nTubize first became a UCB shareholder in 1961. It substantially increased its position in 1981 by acquiring half of Rhône-Poulenc’s UCB securities, while Royale Belge acquired the other half. After gradually taking over Royale Belge’s UCB shares, Tubize’s holding reached 40% in 2002. [P94793830][P29482592][P28775317]\n\nIn 2006, Tubize borrowed €100 million to participate in a UCB capital increase supporting UCB’s acquisition of Schwarz Pharma. On 25 April 2025, Bruno Holthof became chair of Tubize, succeeding Gaëtan Hannecart. [P107804037][https://www.financiere-tubize.be/wp-content/uploads/2025/04/20250429-Communique-de-presse-nomination-BH-comme-president-CA-UK.pdf]\n[P55883835][P108848728][P25111795][P94793830][P29482592][P28775317][P107804037][https://www.financiere-tubize.be/wp-content/uploads/2025/04/20250429-Communique-de-presse-nomination-BH-comme-president-CA-UK.pdf]", "updatedAt": "2026-10-04T15:06:47.526577Z" } ], "sources": [ { "id": "P116594653", "href": "https://app.finbar.com/go?id=P116594653", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p15", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 15 }, { "id": "P8269019", "href": "https://app.finbar.com/go?id=P8269019", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p11", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 11 }, { "id": "P107163778", "href": "https://app.finbar.com/go?id=P107163778", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p4", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 4 }, { "id": "P5594306", "href": "https://app.finbar.com/go?id=P5594306", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p4", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 4 }, { "id": "P25111795", "href": "https://app.finbar.com/go?id=P25111795", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p4", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 4 }, { "id": "https://www.ucb.com/sites/default/files/2026-02/IAR_2025.pdf", "href": "https://www.ucb.com/sites/default/files/2026-02/IAR_2025.pdf", "label": "www.ucb.com" }, { "id": "P79952569", "href": "https://app.finbar.com/go?id=P79952569", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p4", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 4 }, { "id": "P10005445", "href": "https://app.finbar.com/go?id=P10005445", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p4", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 4 }, { "id": "P36293766", "href": "https://app.finbar.com/go?id=P36293766", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p25", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 25 }, { "id": "P18866393", "href": "https://app.finbar.com/go?id=P18866393", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p16", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 16 }, { "id": "P80337790", "href": "https://app.finbar.com/go?id=P80337790", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 5 }, { "id": "https://www.ucb.com/solutions/products/bimzelx", "href": "https://www.ucb.com/solutions/products/bimzelx", "label": "www.ucb.com" }, { "id": "https://www.ucb.com/solutions/products/fintepla", "href": "https://www.ucb.com/solutions/products/fintepla", "label": "www.ucb.com" }, { "id": "https://www.ucb.com/solutions/products/rystiggo", "href": "https://www.ucb.com/solutions/products/rystiggo", "label": "www.ucb.com" }, { "id": "https://www.ucb.com/solutions/products/zilbrysq", "href": "https://www.ucb.com/solutions/products/zilbrysq", "label": "www.ucb.com" }, { "id": "P29783943", "href": "https://app.finbar.com/go?id=P29783943", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p22", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 22 }, { "id": "https://www.financiere-tubize.be/wp-content/uploads/2026/03/20260325-RA-2025-UK.pdf", "href": "https://www.financiere-tubize.be/wp-content/uploads/2026/03/20260325-RA-2025-UK.pdf", "label": "www.financiere-tubize.be" }, { "id": "P55883835", "href": "https://app.finbar.com/go?id=P55883835", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 5 }, { "id": "P108848728", "href": "https://app.finbar.com/go?id=P108848728", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 5 }, { "id": "P94793830", "href": "https://app.finbar.com/go?id=P94793830", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 5 }, { "id": "P29482592", "href": "https://app.finbar.com/go?id=P29482592", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 5 }, { "id": "P28775317", "href": "https://app.finbar.com/go?id=P28775317", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 5 }, { "id": "P107804037", "href": "https://app.finbar.com/go?id=P107804037", "label": "FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5", "documentId": "D-0fdaeda1a8eb465f9e0c29f5d9509258", "page": 5 }, { "id": "https://www.financiere-tubize.be/wp-content/uploads/2025/04/20250429-Communique-de-presse-nomination-BH-comme-president-CA-UK.pdf", "href": "https://www.financiere-tubize.be/wp-content/uploads/2025/04/20250429-Communique-de-presse-nomination-BH-comme-president-CA-UK.pdf", "label": "www.financiere-tubize.be" } ] }